Arsenic sulfde, the main component of realgar, a traditional chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo

Drug Design, Development and Therapy

Volumn 9, Issue , 2014, Pages 79-92

  Zhang, Lian ^a   Tian, Wei ^a,b   Kim, Sungkyoung ^a   Ding, Wenping ^a   Tong, Yingying ^a   Chen, Siyu ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b The Central Hospital of Zibo   (China)

Author keywords

Antitumor; As4S4; P53; Realgar; Xenograft

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ARSENIC DERIVATIVE; ARSENIC SULFIDE; CYCLOPHOSPHAMIDE; EOSIN; FLUORESCEIN ISOTHIOCYANATE; HEMATOXYLIN; LIPOCORTIN 5; PIFITHRIN ALPHA; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARSENIC TRISULFIDE; ORGANOARSENIC DERIVATIVE; SULFIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MEGADOSE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; MTT ASSAY; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CHINESE MEDICINE; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; PATHOLOGY; STOMACH NEOPLASMS; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; TUMOR CELLS, CULTURED;

EID: 84919680363     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S74379     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
3. Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014;20(16):4483–4490.
4. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [homepage on the Internet]. Lyon: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed September 27, 2014.
5. Qiu MZ, Xu RH. The progress of targeted therapy in advanced gastric cancer. Biomark Res. 2013;1(1):32.
6. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-anal-ysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–2909.
7. Wang Z Y. Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol. 2001;48 Suppl 1:S72–S76.
8. Prajapati V, Kale RK, Singh RP. Arsenic and its combinations in cancer therapeutics. Ther Deliv. 2011;2(6):793–806.
9. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88(3):1052–1061.
10. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical effcacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354–3360.
11. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94(10):3315–3324.
12. Sanz MA, Fenaux P, Lo Coco F; European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica. 2005;90(9):1231–1235.
13. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett. 2002;133(1):1–16.
14. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfde for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002; 99(9):3136–3143.
15. Chen SY, Liu SX, Li XM. In vitro study on arsenic sulfide (realgar)-induced apoptosis of retinoic acid susceptible or resistant acute promyelocytic leukemia cell lines. J Med Coll PLA. 2002; 17(1):43–47.
16. Baláž P, Sedlák J. Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview). Toxins (Basel). 2010;2(6):1568–1581.
17. Zhao Y, Wen G, Qiao Z, et al. Effects of tetra-arsenic tetra-sulfde on BXSB lupus-prone mice: a pilot study. Lupus. 2013;22(5): 469–476.
18. Ding WP, Zhang L, Kim SK, et al. Arsenic sulfde as a potential anti-cancer drug. Mol Med Rep. 2015;11(2):968–974.
19. Chen S, Fang Y, Ma L, Liu S, Li X. Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells. Int J Oncol. 2012;40(4):1089–1096.
20. Yin T, Wu YL, Sun HP, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104(13):4219–4225.
21. Wang H, Liu S, Lu X, Zhao X, Chen S, Li X. Gene expression profle changes in NB4 cells induced by realgar. Chin Med J (Engl). 2003;116(7):1074–1077.
22. Vogelstein B, Lane D, Levine AJ. Surfng the p53 network. Nature. 2000;408(6810):307–310.
23. Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem. 2000;275(21):16202–16212.
24. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13(3): 332–337.
25. Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model. Urology. 2000;56(2):332–336.
26. Camp ER, Wang C, Little EC, et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013;20(4): 222–228.
27. Zhao S, Zhang J, Zhang X, Dong X, Sun X. Arsenic trioxide induces different gene expression profles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008;35(3):421–429.
28. Zhao S, Tsuchida T, Kawakami K, Shi C, Kawamoto K. Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol. 2002; 21(1):49–55.
29. Jiang XH, Wong BC, Yuen ST, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 2001;91(2):173–179.
30. Chen SY, Zheng LZ, Liu JW, Li JY, Chen Q. Anticancer effects of realgar on MKN45 cells. Presented at: The 9th International Gastric Cancer Congress (9IGCC); April 20–23, 2011; Seoul. Abstract FP19-9.
31. Zhu GH, Wong BC, Ching CK, Lai KC, Lam SK. Differential apopto-sis by indomethacin in gastric epithelial cells through the constitutive expression of wild-type p53 and/or up-regulation of c-myc. Biochem Pharmacol. 1999;58(1):193–200.
32. Zhang YF, Zhang BC, Zhang AR, et al. Co-transduction of ribosomal protein L23 enhances the therapeutic effcacy of adenoviral-mediated p53 gene transfer in human gastric cancer. Oncol Rep. 2013;30(4): 1989–1995.
33. Li Y, Qu X, Qu J, et al. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 2009;284(2):208–215.
34. Tian Y, Liu Y, He P, et al. Arsenic sulfde promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein. PLoS One. 2014;9(1):e83184.
35. Qi J, He P, Chen W, Wang H, Wang X, Zhang M. Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res. 2010;34(11):1506–1516.
36. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80(2):293–299.
37. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053–1058.
38. Shen Y, Shenk T. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci U S A. 1994;91(19):8940–8944.
39. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277(5):3247–3257.
40. Guo XG, Chen J, Zhang J. As4S4 inducing apoptosis of gastric cancer cells SGC7901. Journal of Modern Oncology. 2013:21(11):2409–2412.
41. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8.
42. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–1286.
43. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55(1):96–107.